Lotessa is a UK-based menstrual and fertility cycle tracking app that uses AI to personalise health insights. While the app itself is functional, the brand lacks meaningful public transparency around its data practices, clinical basis, and company registration details. UK consumers should treat cycle predictions as informational only and not as medical advice.
Lotessa is a femtech application targeting UK women with AI-driven menstrual cycle tracking, fertility insights, and personalised health content. The app is available on iOS and Android and appears to have launched around 2022. Despite claiming a UK base, no corresponding Companies House registration is publicly identifiable, which is a notable gap in corporate transparency for any consumer-facing health product.
The most significant concern for UK consumers is the absence of clinical validation or a named medical team behind the AI predictions. Cycle tracking apps can influence reproductive health decisions, and without MHRA registration or any equivalent oversight, users have no assurance the algorithms meet a verified standard. Additionally, the privacy policy does not clearly enumerate which third-party data processors receive health data — a serious issue given the sensitivity of menstrual and fertility information under UK GDPR.
UK consumers should treat Lotessa as a general wellness journal rather than a reliable medical tool. Do not rely on its predictions for contraception or fertility planning without consulting a qualified healthcare provider. Before subscribing to any premium tier, check whether recurring billing terms are clearly disclosed and confirm cancellation is straightforward — the absence of visible customer support channels makes disputes harder to resolve.